Original Research
Sunday, November 12, 2023
12:45 PM–02:15 PM
Abstract
Introduction: Hyperpolypharmacy is associated with a reduced quality of life and an increased likelihood of side effects. Understanding the factors that place an individual at risk of hyperpolypharmacy is important in designing interventions to address this issue.
Research Question or Hypothesis: What are the risk factors associated with hyperpolypharmacy among older U. S. adults?
Study Design: This is a cross-sectional analysis utilizing U.S. nationally representative data from 2002-2017 Medical Expenditure Panel Survey (MEPS).
Methods: Respondents aged = 65 years were identified within MEPS from 2002-2017. Hyperpolypharmacy was defined as = 10 medications. Potential risk factors collected in MEPS included sociodemographic, clinical, and quality-of-life factors. Survey-weighted logistic regression models were used to determine independent factors associated with hyperpolypharmacy, generating odds ratios and 95% confidence intervals (SAS version 9.4).
Results: Of the ~643 million patients, 15.07% (95% CI 14.61%-15.54%) exhibited hyperpolypharmacy with an average of 12.6 (SE 0.05) medications. Individuals aged 75-84 (compared to 65-74 years) were associated with higher odds of hyperpolypharmacy (aOR, 1.15; 95% CI 1.05-1.25); however, individuals above 85 had lower odds of hyperpolypharmacy (aOR, 0.69; 95%CI 0.60-0.80). Females had lower odds of hyperpolypharmacy (aOR, 0.77; 95%CI 0.70-0.84). Black and Asian race (compared to White) were associated with lower odds of hyperpolypharmacy (aOR, 0.66; 95% CI 0.59-0.74; aOR, 0.53; 95% CI 0.41-0.69, respectively). Fair/poor general health status ratings increased odds of hyperpolypharmacy greatly compared to excellent/very good/good ratings (aOR, 3.70; 95%CI 3.35-4.08). Instrumental daily activity limitations and a usual care source (vs. no source) were both associated with higher odds of hyperpolypharmacy (aOR, 1.68; 95% CI 1.46-1.94; aOR, 4.53; 95% CI 3.71-5.54, respectively).
Conclusion: Our results reveal several factors related to hyperpolypharmacy in the U.S. population with general health status and usual care source being more pronounced. Further work is necessary to investigate the causes of hyperpolypharmacy in these groups and develop interventions to address them.
Presenting Author
Aman R. Patel MSc, PharmD candidateUniversity at buffalo
Authors
Hang Lin BA, PharmD candidate
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
David M. Jacobs PharmD, PhD
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Collin M. Clark PharmD, BCPS, BCGP
University at Buffalo Jacobs School of Medicine and Biomedical Sciences
Steven Feuerstein MS
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Amanda A. Foster PharmD, MPH
University at Buffalo School of Pharmacy and Pharmaceutical Sciences